Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a single center, open label, Phase IIa, multiple-ascending dose study in which
subjects with mild to moderate Cystic Fibrosis and non CF bronchiectasis (n≤12) will be
enrolled.
The safety and tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide
(4%, 8%, and 12% CO2) administered twice daily in subjects with Cystic Fibrosis and non CF
bronchiectasis will be evaluated. This will be followed by 5 day consecutive treatment using
the highest tolerated dose of S1226. Participants can choose additional use of a further four
weeks (28 days) of S-1226 therapy at home, using same or a lower tolerated dose.